Infectious Disease Diagnostics Market to Surpass USD 25.7 Billion Threshold by 2026

The global infectious disease diagnostics market was valued at USD 15,112.2 million in 2017, and is projected to exhibit a CAGR of 6.1 percent from 2018 – 2026. Availability of wide number of diagnostic tests, increasing need for diagnosis of infectious diseases, and high prevalence of infectious diseases is expected to fuel growth of the infectious disease diagnostics market. Cepheid received the US Food & Drug Administration clearance to market Xpert Xpress Strep A test in October 2017, which provides rapid, accurate, and reliable molecular detection of Streptococcus pyogenes. BioMérieux launched Lyme Disease Diagnostic Test in the US in 2015. BioMérieux’s VIDAS Lyme IgG and VIDAS Lyme IgM II assays provide rapid and differential detection of Lyme disease infection. Bio-Rad Laboratories, Inc. introduced BioPlex 2200 Syphilis Total & RPR Assay, a novel Syphilis Testing Method in 2017. Moreover, Bio-Rad Laboratories, Inc. launched Amplichek STI, a molecular infectious disease quality control product for monitoring the performance of in-vitro laboratory nucleic acid testing procedure for detection of sexually transmitted infections in 2017.

Roche Diagnostics launched a HIV test in the US, Elecsys HIV combi PT assay in 2017. This test is capable of detecting the virus about two weeks earlier and can diagnose multiple infectious diseases. Moreover, Roche launched cobas TV/MG in January 2018, for use on the cobas 6800/8800 systems for direct detection of Trichomonas vaginalis (TV) and/or Mycoplasma genitalium (MG) DNA in both symptomatic and asymptomatic individuals. Initiatives and funding from individual organizations to promote research and development of effective diagnostic tests for infectious diseases is expected to boost growth of the infectious disease diagnostics market. For instance, QuantuMDx Group received funding from Bill & Melinda Gates Foundation to develop and test company’s CAPTURE-XT pathogen concentration technology and Q-POC molecular diagnostic platform for rapid low cost detection of tuberculosis in 2016.

In January 2018, University of Glasgow-led project received USD 1.85 million funding, which is a part of Global Challenges Research Fund (GCRF). This project will develop new tests for parasitic diseases, and point-of-care testing in remote locations to help enable rapid diagnosis, and rapid treatment. The Foundation for Innovative New Diagnostics (FIND) announced release of a new strategy in January 2018, which focuses on combatting antimicrobial resistance (AMR) by accelerating the use of diagnostics. FIND announced new collaboration agreements in January 2018, with Becton, Dickinson, and Company (BD), Fondation Botner, the Global Antibiotic Research & Development Partnership (GARDP), the Drugs for Neglected Diseases Initiative (DNDi), and the South African Medical Research Council (SAMRC) that will commence in 2018, to address AMR and other diagnostic challenges in emerging economies. – Coherent Market Insights